Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.38 |
| ▸ | BTN3A1 | O00481 | 8/20 | 0.38 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | LAP3 | P28838 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3967106 | 1.00 | ELANE (0.38) | ELANEBTN3A1PRTN3MAPTLMNA | |
| SCHEMBL4273088 | 0.87 | ELANE (0.38) | ELANEBTN3A1PRTN3ANPEPLAP3 | |
| SCHEMBL873273 | 0.85 | BTN3A1 (0.41) | ELANEBTN3A1PRTN3LMNAANPEP | |
| SCHEMBL3971351 | 0.85 | BTN3A1 (0.41) | ELANEBTN3A1PRTN3LMNAANPEP | |
| SCHEMBL643837 | 0.83 | BTN3A1 (0.40) | ELANEBTN3A1PRTN3LMNAANPEP | |
| SCHEMBL5996997 | 0.83 | BTN3A1 (0.40) | ELANEBTN3A1PRTN3LMNAANPEP | |
| SCHEMBL7027815 | 0.83 | PRTN3 (0.39) | ELANEBTN3A1PRTN3LMNAANPEP | |
| SCHEMBL3970115 | 0.81 | TSHR (0.39) | ELANEBTN3A1PRTN3L3MBTL1 | |
| SCHEMBL3970116 | 0.81 | TSHR (0.39) | ELANEBTN3A1PRTN3L3MBTL1 | |
| SCHEMBL857081 | 0.81 | ELANE (0.48) | ELANEPRTN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009052050-A1 | DIOXOLANE THYMINE PHOSPHORAMIDATES AS ANTI-HIV AGENTS | PHARMASSET, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099136-A1 | DIOXOLANE THYMINE PHOSPHORAMIDATES AS ANTI-HIV AGENTS | PHARMASSET, INC. (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099136-A1 | DIOXOLANE THYMINE PHOSPHORAMIDATES AS ANTI-HIV AGENTS | TYMP, DTYMK, TYMS | ELANE 809/4885BTN3A1 1100/4885PRTN3 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.